KU70 Antibody

What is KU70 and why is it significant in cellular research?

KU70 (also known as XRCC6) is a 70 kDa nuclear protein that forms a heterodimer with KU80 to create the KU complex. This complex plays crucial roles in DNA double-strand break repair through the non-homologous end joining (NHEJ) pathway. Beyond DNA repair, KU70 functions in multiple cellular processes including apoptosis regulation, aging, and viral replication . Its multifunctional nature makes it an important research target across fields including cancer biology, virology, and immunology. When designing experiments targeting KU70, researchers should consider its diverse cellular localizations and functions, as it can be found in both nuclear and cytosolic compartments depending on cellular context.

How do I select the appropriate KU70 antibody for my specific research application?

Selecting the optimal KU70 antibody requires consideration of several experimental parameters. First, determine which applications you require (Western blot, immunofluorescence, immunoprecipitation, etc.) and ensure the antibody is validated for those specific applications. Consider the host species to avoid cross-reactivity with your experimental system. For instance, polyclonal antibodies like GTX101820 demonstrate versatility across applications including Western blot, ICC/IF, IHC-P, IP, and PLA techniques . For more quantitative studies, monoclonal antibodies may offer better reproducibility and specificity. Additionally, verify the antibody's reactivity with your species of interest, as some antibodies are validated only for human and mouse samples . Finally, examine the documentation for data demonstrating the antibody's performance in your intended application.

What are the optimal conditions for using KU70 antibodies in immunofluorescence studies?

For successful immunofluorescence detection of KU70, cell fixation method and antibody dilution are critical parameters. Based on validated protocols, cells should be fixed in 4% paraformaldehyde at room temperature for 15 minutes to preserve cellular architecture while maintaining KU70 antigenicity . For optimal staining, dilute the KU70 antibody (e.g., GTX101820) at 1:200 in appropriate blocking buffer. Include a cytoskeleton marker like phalloidin (diluted 1:200) for co-localization context, particularly when studying potential cytoplasmic functions of KU70. Confocal microscopy is recommended for precise subcellular localization, as KU70 demonstrates primarily nuclear localization in most cell types, with potential cytoplasmic expression under specific conditions such as DNA damage or viral infection . For quantitative analysis, establish standardized exposure settings and include appropriate controls to account for background fluorescence and non-specific binding.

How can I optimize Western blot protocols for KU70 detection in different cell types?

Optimizing Western blot protocols for KU70 requires attention to several technical considerations. For cell lysis, use buffers containing protease inhibitors to prevent degradation of KU70, which has been shown to be susceptible to proteolytic degradation. Load 20-30 μg of total protein per lane on a 7.5% SDS-PAGE gel for optimal resolution of the 70 kDa KU70 protein . After transfer to a membrane, block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature. Incubate with primary KU70 antibody (e.g., GTX101820 at 1:2000 dilution) overnight at 4°C for optimal sensitivity . For detection, use HRP-conjugated secondary antibodies with appropriate species reactivity. When comparing KU70 expression across different cell types, include a reliable loading control (β-actin) and consider that KU70 expression levels may vary significantly between cell types, particularly in cancer cell lines versus primary cells. Quantify band intensity using image analysis software after normalization to loading controls.

What protocols are recommended for studying KU70-DNA binding interactions in vitro?

For analyzing KU70-DNA binding interactions, researchers have several methodological options. The traditional electrophoretic mobility shift assay (EMSA) involves incubating nuclear extracts with radioactive double-stranded oligonucleotide probes and resolving samples by electrophoresis on native polyacrylamide gels . While sensitive, this approach is time-consuming and requires radioactive materials. A more efficient alternative is the ELISA-based DNA Repair Kit, which utilizes 96-well plates with immobilized linear oligonucleotides featuring blunt ends. KU70/86 in nuclear extracts binds to these oligonucleotides and is detected using primary antibodies that recognize epitopes accessible upon DNA binding, followed by HRP-conjugated secondary antibodies for colorimetric quantification . This method is approximately 20-fold faster than gel retardation techniques, can detect KU70 activation with as little as 0.15 μg of nuclear extract, and allows high-throughput analysis of multiple samples . For optimal results, use 2-10 μg of cell extract diluted in complete lysis buffer per well, and include appropriate positive controls (e.g., 2.5 μg Raji nuclear extract) and blank wells.

How can I effectively study KU70's role in innate immunity as a cytosolic DNA sensor?

Investigating KU70's function as a cytosolic DNA sensor requires specialized experimental approaches. First, establish cellular compartment-specific fractionation protocols to clearly distinguish between nuclear and cytosolic KU70 pools. Next, design stimulation experiments using various DNA structures (linear, circular, single-stranded, double-stranded) to determine binding specificity. To assess downstream signaling, monitor type I and type III interferon induction and proinflammatory cytokine production through qPCR, ELISA, or reporter assays following DNA stimulation . For mechanistic studies, implement RNA interference approaches targeting KU70 using validated shRNA sequences (e.g., 5′-CCGGCGACATAAGTCGAGGGACTTTCTCGAGAAAGTCCCTCGACTTATGTCGTTTTTG-3′) . When designing knockdown experiments, carefully assess knockdown efficiency through Western blot analysis and normalize to endogenous controls like β-actin . To confirm specificity, include rescue experiments with KU70 constructs resistant to the shRNA. For protein interaction studies, combine co-immunoprecipitation with mass spectrometry to identify novel binding partners involved in innate immune signaling cascades.

What methodologies are recommended for investigating KU70-HIV integrase interactions?

Studying KU70-HIV integrase interactions requires multiple complementary approaches. For protein-protein interaction analysis, implement cell-based co-immunoprecipitation assays using antibodies against either protein, followed by Western blot detection of binding partners . To investigate the protective effect of KU70 on HIV-1 integrase, employ ubiquitination assays by co-transfecting cells with GFP-tagged integrase and HA-tagged ubiquitin constructs (wild-type or K48R and K63R mutants) in the presence or absence of T7-tagged KU70 constructs . After immunoprecipitation with anti-GFP antibody, assess ubiquitination levels through Western blot using HRP-conjugated anti-HA antibody. For functional studies, establish KU70 knockdown cell lines using lentiviral-delivered shRNA, followed by HIV infection assays to evaluate viral replication efficiency . Complementary approaches include direct immunofluorescence assays with GFP-tagged integrase expression in KU70-depleted cells, with or without proteasome inhibitors like MG-132 (10 μM), to visualize integrase stability and localization . For measuring protein degradation kinetics, implement pulse-chase experiments combined with cycloheximide treatment to block new protein synthesis.

What are the current approaches to study post-translational modifications of KU70 and their functional consequences?

Studying post-translational modifications (PTMs) of KU70 requires sophisticated methodology. First, employ mass spectrometry-based proteomics approaches, specifically enriching for phosphorylation, acetylation, ubiquitination, and SUMOylation, which have been reported to regulate KU70 function. For acetylation studies, which influence KU70's interaction with Bax and apoptotic regulation, combine immunoprecipitation with anti-acetyl lysine antibodies followed by KU70 detection. For functional analysis, implement site-directed mutagenesis to generate KU70 constructs with lysine-to-arginine or lysine-to-glutamine mutations at key acetylation sites, followed by functional readouts including DNA repair efficiency, protein-protein interactions, and cellular localization. To study dynamic regulation of KU70 PTMs, employ specific inhibitors of deacetylases (e.g., HDAC inhibitors), kinases, or phosphatases relevant to KU70 regulation. For ubiquitination analysis, co-express HA-tagged ubiquitin with KU70 constructs, followed by denaturing immunoprecipitation to prevent co-purification of ubiquitinated binding partners . Advanced approaches include proximity ligation assays to visualize specific KU70 modifications in situ within cells, and CRISPR-Cas9 genome editing to introduce endogenous mutations at PTM sites for physiologically relevant studies.

How can I address issues with KU70 antibody specificity and cross-reactivity in my experiments?

When encountering specificity concerns with KU70 antibodies, implement a systematic validation approach. First, perform Western blot analysis across multiple cell lines, expecting a single band at approximately 70 kDa. Include a KU70 knockdown control using validated siRNA or shRNA sequences to confirm band specificity . For immunoprecipitation applications, include preimmune IgG controls to assess non-specific binding, as demonstrated with the GTX101820 antibody validation . When using immunofluorescence, perform peptide competition assays where the antibody is pre-incubated with purified KU70 protein before staining. Additionally, validate nuclear localization patterns by co-staining with nuclear markers and comparing to published KU70 localization data. For cross-reactivity concerns between species, test the antibody on samples from multiple species and compare with species-specific positive controls. When studying KU70 in tissues or cells expressing high levels of related proteins (e.g., KU80), perform parallel experiments with antibodies targeting distinct epitopes on KU70 to confirm consistent patterns. Finally, consider using multiple detection methods (e.g., mass spectrometry) to verify findings from antibody-based approaches.

What controls should be implemented when studying KU70 activation in DNA repair assays?

When investigating KU70 activation in DNA repair assays, a comprehensive control strategy is essential. For ELISA-based DNA repair kits, include positive controls using 2.5 μg of validated nuclear extract (e.g., Raji nuclear extract) and blank wells containing only lysis buffer to establish baseline readings . To validate nuclear extract quality, perform parallel Western blot analysis confirming KU70 expression. Include time-course controls following DNA damage induction to establish appropriate kinetics for KU70 activation. For specificity validation, implement competitive binding assays using excess unlabeled oligonucleotides with various end structures to confirm binding specificity to DNA breaks. When using cells with genetic manipulations of KU70, include wild-type, knockdown, and rescue conditions to demonstrate specificity. For pharmacological studies targeting KU70 activity, include dose-response controls and validation of compound specificity using structural analogs. Additionally, perform parallel assays measuring functional outcomes of DNA repair (e.g., comet assay, γH2AX foci resolution) to correlate KU70 activation with repair efficiency. When comparing KU70 activation across different cell types or conditions, normalize to total KU70 protein levels to distinguish between changes in activation versus expression.

What are the emerging techniques for studying KU70's role in different subcellular compartments?

Emerging techniques for investigating KU70's compartment-specific functions include several cutting-edge approaches. Super-resolution microscopy methods such as STORM and PALM offer nanoscale visualization of KU70 localization relative to specific subcellular structures, providing insights beyond conventional confocal microscopy. For dynamic studies, implement live-cell imaging with KU70 tagged with photoactivatable fluorescent proteins to track its movement between compartments following stimuli such as DNA damage or viral infection . Proximity labeling methods including BioID or APEX2 fused to KU70 enable compartment-specific interactome mapping by biotinylating proteins in close proximity to KU70 in different cellular locations. For functional dissection, design KU70 constructs with compartment-specific targeting signals (nuclear localization or export signals) combined with endogenous KU70 depletion to selectively rescue compartment-specific functions. Single-molecule tracking approaches can provide insights into the mobility and DNA binding dynamics of KU70 in the nucleus versus cytoplasm. Finally, spatial proteomics combining subcellular fractionation with quantitative mass spectrometry can comprehensively map KU70 distribution and modification status across all cellular compartments simultaneously, revealing novel locations and potential functions.

How can I design experiments to investigate the dual roles of KU70 in DNA repair and innate immunity?

Designing experiments to dissect KU70's dual functions requires sophisticated approaches to separate these potentially overlapping pathways. First, establish cellular systems with domain-specific KU70 mutants that selectively disrupt either DNA binding (affecting DNA repair) or protein interaction domains (potentially affecting innate immune signaling). Implement CRISPR-Cas9 knock-in strategies to introduce these mutations at endogenous loci. To temporally separate these functions, design synchronized experimental systems where cells are arrested in specific cell cycle phases (where DNA repair activity varies) followed by immune stimulation. For pathway-specific analysis, utilize selective inhibitors of downstream signaling components unique to either DNA repair or innate immune responses, while monitoring KU70 recruitment and function . Employ chromatin immunoprecipitation followed by sequencing (ChIP-seq) to map KU70 binding to chromosomal versus foreign DNA, potentially revealing distinct binding patterns. For protein interaction studies, perform quantitative interactome analysis under conditions selectively activating either DNA repair (e.g., ionizing radiation) or innate immunity (e.g., cytosolic DNA transfection), identifying pathway-specific binding partners . Finally, develop dual-reporter systems with distinct readouts for DNA repair efficiency and innate immune activation to simultaneously monitor both functions in single cells.

What methodological advances are needed to study the therapeutic targeting of KU70 in cancer and viral infections?

Advancing therapeutic approaches targeting KU70 requires several methodological innovations. First, develop high-throughput screening platforms combining the efficiency of ELISA-based DNA repair kits with cell-based reporter systems to identify compounds that selectively modulate KU70's DNA repair versus innate immune functions. Establish patient-derived organoid models to evaluate KU70-targeting strategies in physiologically relevant systems with intact tumor microenvironments. For selectivity assessment, implement CRISPR-Cas9 screening to identify synthetic lethal interactions with KU70 inhibition, potentially revealing cancer-specific vulnerabilities. Develop quantitative pharmacodynamic markers of KU70 inhibition for in vivo studies, potentially using imaging approaches with antibodies recognizing inhibition-specific conformational changes. For viral studies, establish physiologically relevant infection models that accurately recapitulate KU70-viral protein interactions, particularly for HIV integrase protection . Design bifunctional degraders (PROTACs) specifically targeting KU70 to achieve more complete protein inhibition than conventional approaches. Implement combinatorial drug screening to identify synergistic interactions between KU70 inhibitors and established cancer therapies or antivirals. Finally, develop biomarker strategies to identify patient populations likely to respond to KU70-targeting approaches, potentially based on expression levels, mutation status, or pathway dependencies in tumor or immune cells.